These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 17259594)
1. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? Quaggin SE; Coffman TM J Am Soc Nephrol; 2007 Feb; 18(2):364-6. PubMed ID: 17259594 [No Abstract] [Full Text] [Related]
2. A breakthrough in diabetic nephropathy: the role of endothelial dysfunction. Nakagawa T; Segal M; Croker B; Johnson RJ Nephrol Dial Transplant; 2007 Oct; 22(10):2775-7. PubMed ID: 17595179 [No Abstract] [Full Text] [Related]
3. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434 [TBL] [Abstract][Full Text] [Related]
5. Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathy. Komers R; Anderson S Nephrol Dial Transplant; 2008 Sep; 23(9):3037; author reply 3037-8. PubMed ID: 18596128 [No Abstract] [Full Text] [Related]
6. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Hohenstein B; Hugo CP; Hausknecht B; Boehmer KP; Riess RH; Schmieder RE Nephrol Dial Transplant; 2008 Apr; 23(4):1346-54. PubMed ID: 18065828 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Balakumar P; Chakkarwar VA; Krishan P; Singh M Biomed Pharmacother; 2009 Mar; 63(3):171-9. PubMed ID: 18823739 [TBL] [Abstract][Full Text] [Related]
8. [Model's short life and murine resistance, another ''no'' revolution]. Cornacchia F G Ital Nefrol; 2007; 24(4):282. PubMed ID: 17659494 [No Abstract] [Full Text] [Related]
13. A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism. Nakagawa T Clin Nephrol; 2009 Feb; 71(2):103-9. PubMed ID: 19203501 [TBL] [Abstract][Full Text] [Related]
14. Can rodent models of diabetic kidney disease clarify the significance of early hyperfiltration?: recognizing clinical and experimental uncertainties. Levine DZ Clin Sci (Lond); 2008 Jan; 114(2):109-18. PubMed ID: 18062776 [TBL] [Abstract][Full Text] [Related]
15. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Sato W; Kosugi T; Zhang L; Roncal CA; Heinig M; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Grant MB; Croker BP; Nakagawa T Lab Invest; 2008 Sep; 88(9):949-61. PubMed ID: 18607348 [TBL] [Abstract][Full Text] [Related]
16. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Isermann B; Vinnikov IA; Madhusudhan T; Herzog S; Kashif M; Blautzik J; Corat MA; Zeier M; Blessing E; Oh J; Gerlitz B; Berg DT; Grinnell BW; Chavakis T; Esmon CT; Weiler H; Bierhaus A; Nawroth PP Nat Med; 2007 Nov; 13(11):1349-58. PubMed ID: 17982464 [TBL] [Abstract][Full Text] [Related]
17. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Cheng H; Wang H; Fan X; Paueksakon P; Harris RC Kidney Int; 2012 Dec; 82(11):1176-83. PubMed ID: 22785174 [TBL] [Abstract][Full Text] [Related]
18. The endothelium in diabetic nephropathy. Advani A; Gilbert RE Semin Nephrol; 2012 Mar; 32(2):199-207. PubMed ID: 22617769 [TBL] [Abstract][Full Text] [Related]
19. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Woo CH; Shishido T; McClain C; Lim JH; Li JD; Yang J; Yan C; Abe J Circ Res; 2008 Mar; 102(5):538-45. PubMed ID: 18218985 [TBL] [Abstract][Full Text] [Related]
20. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model. Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]